



FIDELIS CARE®

# Office Based Addiction Treatment (OBAT)

## Did You Know?

Section 1262 of the Consolidated Appropriations Act, 2023 (also known as Omnibus bill), removes the federal requirement for practitioners to submit a Notice of Intent (have a waiver) to prescribe medications, like buprenorphine, for the treatment of opioid use disorder (OUD). With this provision, and **effective immediately**, SAMHSA will no longer be accepting NOIs (waiver applications).

For more information please visit: [www.samhsa.gov](http://www.samhsa.gov)



All practitioners who have a current DEA registration that includes Schedule III authority, may now prescribe buprenorphine for Opioid Use Disorder in their practice.



If you would like to be identified as an OBAT provider please contact:

Behavioral Health Providers: [Melanny.Zerna@fideliscarenj.com](mailto:Melanny.Zerna@fideliscarenj.com)

PCP Providers: [Yvette.James@fideliscarenj.com](mailto:Yvette.James@fideliscarenj.com)